Abstract
Sacral neuromodulation involves a staged process, including a screening trial and delayed formal implantation for those with substantial improvement. The advent of the tined lead has revolutionized the technology, allowing for a minimally invasive outpatient procedure to be performed under intravenous sedation. With the addition of fluoroscopy to the bilateral percutaneous nerve evaluation, there has been marked improvement in the placement of these temporary leads. Thus, the screening evaluation is now a better reflection of possible permanent improvement. Both methods of screening have advantages and disadvantages. Selection of a particular procedure should be tailored to individual patient characteristics. Subsequent implantation of the internal pulse generator (IPG) or explantation of an unsuccessful staged lead is straightforward outpatient procedure, providing minimal additional risk for the patient. Future refinement to the procedure may involve the introduction of a rechargeable battery, eliminating the need for IPG replacement at the end of the battery life.
Similar content being viewed by others
References
Stewart WR (2001) Prevalence and impact of OAB in the US: results from the NOBLE program. Neurol Urodynam 20:406–408
Tanagho EA, Schmidt RA (1988) Electrical stimulation in the clinical management of the neurogenic bladder. J Urol 140:1331–1339
Bullock TL, Siegel SW (2010) Sacral neuromodulation for voiding dysfunction. In: Statskin D (ed) Atlas of bladder disease. Springer, Philadelphia, pp 1–12
Siegel SW (1992) Management of voiding dysfunction with an implantable neuroprosthesis. Urol Clin NA 19:163–170
Spinelli M, Giardiello G, Gerber M, Arduini A, van den Hombergh U, Malaguti S (2003) New sacral neuromodulation lead for percutaneous implantation using local anesthesia: description and first experience. J Urol 170:1905–1907
Acknowledgements
We acknowledge Medtronic, Minneapolis, MN for their contribution in this paper.
Conflicts of interest
E.R. Williams is a consultant of AMS. S.W.E. Siegel is an investigator and consultant/advisor for Uroplasty; a consultant/advisor for QIG; an investigator at Boston Scientific; a board member, officer, and trustee at the North Central Section AUA; an investigator and consultant/advisor for Allergan; a consultant/advisor for Bard Urological; is involved in a scientific trial at Uromedica; a board member, officer, and trustee at SUFU; an investigator and consultant/advisor and part of the scientific trial at AMS; an investigator and consultant/advisor and is part of the scientific trial at Medtronic; and a consultant/advisor for GT Medical.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Williams, E.R., Siegel, S.W. Procedural techniques in sacral nerve modulation. Int Urogynecol J 21 (Suppl 2), 453–460 (2010). https://doi.org/10.1007/s00192-010-1280-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00192-010-1280-4